In many acute leukemias and some lymphomas, aberrant dierentiation is a major feature of the malignant phenotype that often results from a single genetic alteration and hence provides a site-speci®c target for therapy (Look, 1997) . The oncogenic event frequently leads to the generation of a fusion gene that facilitates proliferation by inhibiting a tumor suppressor gene and also disrupts signaling pathways required for dierentiation (Melnick and Licht, 1999) . In many cell lines and primary cultures derived from hematologic malignancies the malignant phenotype can be abrogated by inducing dierentiation, terminal cell division or programmed cell death (apoptosis) by a variety of agents (Table 1) (Ferrari and Waxman, 1994) . Interestingly, many of these agents at low concentrations induce dierentiation and terminal cell division with minimal apoptosis while at higher concentration, usually by an alternative pathway, induce apoptosis with minimal evidence of dierentiation (Finnin et al., 1999; Maurer et al., 1999; Richon et al., 2001; Suh et al., 1999; Wu et al., 2001) . Thus, the therapeutic outcome of dierentiation therapy should be correlated with measurement of dierentiation, loss of clonogenicity and apoptosis. Dierentiation therapy can be used with or following cycles of cytotoxic chemotherapy. This combination cytotoxic-dierentiation therapy results in enhanced apoptosis, prevention of regrowth of malignant cells and drug resistance and induction of dierentiation-speci®c targets, which should increase the chance for cure (Figure 1 ) (Hozumi, 1998; Huang and Waxman, 1998; Niitsu and Honma, 1999; Waxman, 2000; Waxman et al., 1990) .
In leukemic cell lines and primary cultures treatment with Biomodulators (hematopoietic growth factors, TGFb, vitamin D, retinoic acid butyrates, free fatty acids, interferons) and cyclic nucleotides and Chemical agents (DMSO, histone deacetylase inhibitors (HDACi), HMBA, TPA, certain cytotoxic agents) alone, or in combination, results in a similar scenario during the process of induced dierentiation. This typically includes a stochastic program of early in¯ux of calcium, protein kinase C translocation and activation, G 1 cell cycle arrest associated with p53 dependent or independent p21
WAF1 induction, retinoblastoma protein hypophosphorylation, a decrease in growthassociated genes such as c-myc, c-myb, and an early increase in anti-apoptotic proteins (Rifkind et al., 1996; Scher et al., 1982b; Waxman, 2000) . Thereafter an array of lineage dierentiation speci®c gene expressions is followed by commitment to terminal cell division often with the expression of an apoptotic program (Altucci et al., 2001; Liu et al., 2000) . The activation of speci®c signaling pathways are dierentiation agent and cell type speci®c. Dierentiation induction of hematologic malignant cells as well as normal hematopoeitic stem cell dierentiation is mediated by a stochiometric ratio of transcription factors such as GATA-1 and PU-1 (Rekhtman et al., 1999) which broadly determine lineage and cooperate with more speci®c transcription factors such as RAR receptor and CEBP family members (Matushansky et al., 2000; Park et al., 1999; Tenen et al., 1997) . Erythropoietin (EPO) induced erythrodierentiation of leukemic cells is associated with GATA-1 induction and downregulation of PU-1 and other transcription factors that direct myeloid lineage during normal dierentiation. Conversely, myeloid dierentiation of A4 murine progenitor cells by GCSF or GMCSF increases RARa2 whereas erythrodierentiation induced by EPO downregulates RARa2 (Zhu et al., 2001) . Therefore, with appropriate stimulation the regulatory pathways involved in hematopoeitic dierentiation can be re-activated in hematopoeitic malignant cells. Targeting the molecular defect that interferes with the normal regulatory pathway may provide such a stimulus and serve as the basis of dierentiation therapy. A paradigm for dierentiation therapy of hematologic malignancies is provided by the successful development of all trans-retinoic acid (RA) therapy and elucidation of its molecular mechanism in acute promyelocytic leukemia (APL).
Dierentiation therapy is eective in APL
APL is a subtype of acute myeloblastic leukemia (AML) characterized by the uncontrolled expansion of promyelocytes and a block in normal granulocytic dierentiation. APL provides a unique model in cancer treatment due to two signi®cant features: (1) essentially all known cases of APL are associated with chromosomal translocations involving the retinoic acid receptor gene (RARa) (Figure 2 ) and (2) these patients achieve high clinical remission rates in response to dierentiation therapy with all trans retinoic acid (RA), the ligand that also binds to the rearranged receptor.
For many years, treatment of APL was restricted to aggressive chemotherapy that, when successful, eliminated the malignant clone. In 1988, a Chinese group reported dramatic clinical responses to oral therapy with RA, an active form of vitamin A (Huang et al., 1988) . They, and subsequently researchers in France and the USA, demonstrated a novel mechanism by which these responses were obtained (Castaigne et al., 1990; Warrell et al., 1991) . RA induces APL blasts to terminally dierentiate along a neutrophilic pathway, without any evidence of direct cytotoxic eects. Although clinical relapse occurs commonly after treatment with RA alone, large multicenter randomized trials have demonstrated that RA in combination with chemotherapy results in a higher rate of durable remission and survival than chemotherapy alone, with a potential cure in nearly 70% of patients (Fenaux et al., 1994; Sanz et al., 2000) . Thus, treatment of APL with retinoids provides the ®rst dramatic demonstration of ecacy of dierentiation therapy in an advanced malignancy.
These dramatic clinical results were followed by extensive research into the mechanisms of RA-induced dierentiation in APL. The overwhelmingly most common translocation of APL fuses RARa with the PML gene, producing a fusion protein that has been demonstrated to cause an APL-like syndrome when expressed in transgenic mice. The PML/RARa fusion protein retains most of the functional domains of both PML and RARa (Dyck et al., 1994; Weis et al., 1994) . The break in RARa invariably is located within the second intron resulting in an RARa protein with only the initial A segment missing (Figure 2 ). The PMLRARa protein acts as an aberrant retinoid receptor with additional functional properties.
The dominant negative eect of the PML/RARa fusion protein on retinoid signaling has been explained Lin et al., 1998) . In the absence of ligand, retinoid receptors bind DNA and associate with corepressor complexes that include histone deacetylases, which keep the histones around the target gene promoter deacetylated and the chromatin in the`closed' conformation. In the presence of ligand corepressors dissociate from the retinoid receptors, allowing recruitment of transcriptional coactivators and activation of the transcription machinery ( Figure 3 ). The coactivators associate with, or function as, histone acetyltransferases that cause the chromatin to adopt an open conformation allowing the initiation of target gene transcription Guidez et al., 1998; Lin et al., 1998) . The PML-RARa oncoprotein requires 100 ± 1000-fold higher concentration of RA for release of corepressors and recruitment of coactivators. This tighter binding of PML-RARa to the corepressor complex, results in transcriptional repression at physiologic levels of RA and inactivation of critical retinoid receptor target genes in myeloid development that may be the basis for the dierentiation block. The release of corepressors at pharmacologic concentrations of RA correlates well with the observed induction of dierentiation in vitro and in vivo. Moreover, RA treatment results in caspase-dependent PMLRARa cleavage that directly removes the leukemogenic fusion gene product . There is also evidence that the PML/RARa fusion gene product inhibits normal PML function, and that this may contribute to the pathogenesis of APL. The PML phosphoprotein is found in both the nucleus and the cytoplasm, but highest expression is found in PML nuclear bodies, which form a framework in the nuclear matrix that may direct chromatin folding and nucleic acid tracking (van Driel et al., 1991) . PML is believed to act as a tumor suppressor, based on reports that PML overexpression confers a growth disadvantage and suppresses transformation by cooperative oncogenes (Ahn et al., 1995; Mu et al., 1994) , while PML knock-out mice have increased susceptibility to infections and tumor development (Wang et al., 1998a) . The PML-RARa fusion protein likely disrupts the growth suppressive activity of PML, thus allowing the expansion of immature promyelocytes. This is supported by the observation that the normally punctate PML protein localization is disrupted to a microparticulate pattern by fusion to RARa in APL cells (Dyck et al., 1994; Mu et al., 1994; Weis et al., 1994) . Immunohistochemical studies with both anti-PML and anti-RARa antibodies showed that in APL cells, PML co-localizes with PML-RARa and is subsequently displaced from the nuclear body structure. PML staining is returned from the microparticulate pattern to the normal discrete punctate staining after treatment with RA (Dyck et al., 1994; Weis et al., 1994) . The relative importance of the restoration of RAR-and PML-speci®c pathways in RA-induced dierentiation is not well de®ned. In patients with PML-RARa, pharmacologic doses of RA can convert the PMLRARa protein from a dominant negative inhibitor of retinoid-regulated transcription to an activator. However, RA also induces cleavage of the PML-RARa protein, which appears to be required for the restoration of normal PML nuclear body structure. It is not entirely clear whether the RA-induced transcriptional activity or PML-RARa cleavage or both are responsible for APL cell dierentiation.
Mechanisms of resistance to RA induced dierentiation therapy
Although RA has proven to be an eective therapy for APL patients, RA treatment alone rarely induces a durable remission, and patients are often refractory to RA treatment upon relapse. Two mechanisms have been proposed to contribute to the development of RA resistance. Firstly, RA induces its own metabolic degradation, so that RA levels could be decreased to levels below the threshold for cytodierentiation. In fact, RA-resistance has been associated with reduced plasma RA concentrations. This decrease is not APL-speci®c, as decreased plasma RA concentrations are also seen after RA treatment in patients with lung cancer or other solid tumors. However, APL blasts from RA-resistant patients often fail to dierentiate in vitro in response to high doses of RA, suggesting other mechanisms of resistance. Indeed, cellular retinoic acid binding proteins (CRABPs), which function to sequester and inactivate RA, have been shown to increase in APL cells with RA treatment (Cornic et al., 1994; Delva et al., 1993; Muindi et al., 1992) . However, 9-cis RA, an isomer of all-trans RA that maintains more stable plasma concentrations during extended treatment (Miller et al., 1995) and does not bind CRABPs, fails to reverse the acquired clinical resistance in APL patients who have been previously treated with all-trans RA (Miller et al., 1995) . Physiologic concentrations of RA trigger the release of corepressors and the association of coactivators (P/CAF, p160 family members, CBP/p300, and DRIP/TRAP/ARC complexes) that facilitate transcription via histone acetylation leading to dierentiation. In APL cells, PML-RARa binds the RARE and corepressor molecules, but only at pharmacologic doses of RA does PML-RARa release the corepressor complex, recruit coactivators, and initiate transcription. The acquisition of PML-RARa mutations that no longer respond to pharmacologic doses of RA causes RA-resistant APL. In some cases, the use of arsenic or HDAC inhibitors in conjunction with RA can release the transcriptional block Furthermore, synthetic RAR-speci®c ligands not metabolized by cellular P450 enzymes are not able to overcome RA-resistance in vitro or in patients (Takeuchi et al., 1998) . Therefore, increasing plasma retinoid concentrations alone is not sucient to overcome retinoid resistance, suggesting additional mechanisms for the development of RA resistance. A second hypothesis proposes genetic lesions as the cause of RA resistance. Point mutations have been identi®ed in the ligand binding domain of the fusion gene PML-RARa in cultured RA-resistant APL subclones as well as in relapsed patients (Ding et al., 1998; Imaizumi et al., 1998) . A mutation was reported in an RA-resistant subclone that no longer responded to pharmacological concentrations of RA and functioned as a dominant negative inhibitor of RA-dependent transcriptional activation, thereby blocking cytodierentiation (Shao et al., 1997) . The mutated PML-RARa has lost the ability to bind ligand, and as a result constitutively associates with the corepressor SMRT and fails to interact with coactivator ACTR in a liganddependent manner (Cote et al., 2000) (Figure 3 ). Other groups soon reported several mutations arising in APL cells from RA-resistant patients. These mutations localize to two regions involved in forming the RAbinding pocket of PML-RARa and show alterations in ability to bind ligand and nuclear receptor co-regulators . Finding point mutations in relapsed APL patients con®rmed the results obtained in the cellular models, indicating that stable genetic lesions in the PML-RARa oncoprotein account for an important mechanism mediating RA resistance. Still, not all RA-resistant cell lines and relapsed APL patients harbor mutations in PML-RARa, suggesting there are alternative mechanisms of RA-resistance. One such mechanism may be resistance to RA induced PML RARa protein cleavage shown in some dierentiation resistant APL cell lines (Jing et al., 2001) .
Arsenic trioxide: a second novel and highly eective therapy for APL involving dierentiation Only a few years after the ®rst reports of dramatic success of RA in the treatment of APL, Chinese researchers described the induction of remission in patients with APL using arsenic trioxide at concentrations that had limited side eects. These trials showed that arsenic induces complete remissions in 70 ± 90% of newly diagnosed patients with APL and in 65 ± 90% of relapsed patients (Niu et al., 1999; Shen et al., 1997) . These studies have been con®rmed by data from the USA showing that low doses of arsenic trioxide can induce complete remissions in relapsed APL patients (Soignet et al., 1998) . Although, compared to other leukemic cell types, APL cells appear particularly sensitive to arsenic, in vitro activity in a variety of cancer cell lines has led to active clinical research in other malignancies Shao et al., 1998) .
The mechanism of arsenic action in APL bears similarities and dierences to that of RA. While RA speci®cally targets the aberrant fusion receptor PML/ RARa, arsenic aects numerous cellular signaling pathways, and can lead to growth inhibition, the induction of apoptosis, or in some circumstances, dierentiation Shao et al., 1998; Wang et al., 1998b) . Arsenic trioxide produces remissions in APL, at least in part, through a mechanism that results in the degradation of the PML/RARa fusion oncoprotein responsible for the development of the disease. The loss of PML/RARa releases its dominant negative block on RAR function, allowing granulocytic dierentiation of the malignant clone (Figure 3) . The degradation of PML/RARa protein, unlike RA, results from arsenic-induced covalent modi®cation of the PML portion of the molecule by Sumo-1, a ubiquitin-like protein whose attachment may target the protein for proteasomal degradation . Since modi®cation of wildtype PML is also induced by arsenic, it is possible that alterations in the function of PML may contribute to the response to arsenic in APL cells. Although it is reasonable to assume that the release of the dierentiation block by PML/RARa should lead to dierentiation, the data to date are more complicated. In APL cells treated in vitro with micromolar concentrations of arsenic trioxide, which are attainable in patients, apoptosis without evidence of dierentiation is observed. Indeed, when NB4 cells or fresh APL cells from untreated patients are exposed to the combination of RA and arsenic in vitro, arsenic inhibits RA-induced dierentiation Shao et al., 1998) . However, in several models of cells resistant to dierentiation by RA alone, sub-apoptotic concentrations of arsenic can synergize with RA to induce dierentiation (Lallemand-Breitenbach et al., 1999; Rego et al., 2000) .
When used in vivo, there is additional evidence that arsenic trioxide can induce dierentiation. Patients with APL, most of whom had relapsed after RA treatment, were reported to show evidence of cellular dierentiation while achieving remission following arsenic treatment (Soignet et al., 1998) . Mouse models of APL have also shown a possible synergy between arsenic and RA, although it has not been determined whether a sequential or a concurrent administration of the two agents is more ecient (Lallemand-Breitenbach et al., 1999) .
Arsenic induced apoptosis, both in APL and other malignant cells occurs by a process that appears independent of its actions on the PML/RARa fusion protein Davison et al., 1999) . Rather, the response to As 2 O 3 may be linked to the biochemical environment within the cell. Cancer cell lines vary substantially in their sensitivity to arsenic-induced apoptosis, and there is evidence the intracellular redox and reduced glutathione (GSH) levels within a cell are predictive of arsenic responsiveness Yang et al., 1999) . Arsenic has been reported to inhibit glutathione reductase and decrease GSH levels within the cell (Cunningham et al., 1994) . Consistent with these data, in all malignant cell models tested, arsenic-induced apoptosis is enhanced by BSO, which depletes glutathione levels. Also, apoptosis is inhibited by treatments that increase cellular GSH levels.
Where and how to design dierentiation therapy?
Therapeutic targeting of enzymes involved in aberrant transcription in APL Multi-protein complexes containing activities that modify and remodel chromatin structure contribute to the control of gene regulation and are often aberrant in hematologic malignancies and inhibit the process of dierentiation. The enzymatic activities present in such complexes include histone deacetylases (HDACs), histone acetyltransferases (HATs), DNA methyl-transferases and ATP dependent remodeling complexes (Jenuwein and Allis, 2001) .
A misuse of histone deacetylase may lead to transcriptional repression of key genes causing aberrant dierentiation with uncontrolled proliferation of immature blood cells in several forms of acute myeloid leukemia (AML) associated with single chromosomal translocation. In t(8;21) AML type M-2 (Downing, 2001) , the DNA binding domain of AML-1 is fused with a protein known as ETO, which interacts with corepressors associated with histone deacetylase resulting in repression of cell dierentiation (Amann et al., 2001; Downing, 1999; Minucci et al., 2001) (Figure 2) . Similarly, in t(12;21) (p13;q22)-TEL-AML-1 associated common childhood acute lymphoblastic leukemia recruits N-CoR to the TEL moiety (Guidez and Zelent, 2001 ). In APL, in vitro and in vivo animal models demonstrate the ecacy of combining RA with HDAC inhibitors (HDACi) such as butyrates or trichostatin A for more eective dierentiation induction and therapeutic response (Guidez et al., 1998; Kosugi et al., 2001; Lin et al., 1998; Warrell et al., 1998) . This may relate in part to the observation that oligomerization of RARa, through a self-association domain present in PML, results in an interaction with transcriptional coregulators with recruitment of histone deacetylases. This seems to be correlated and required for transcriptional repression of PML-RAR target genes (Lin and Evans, 2000) . Oligomerization and recruitment of HDACs may also contribute to the transformation by the AML-1 ETO fusion gene, extending these mechanisms to other forms of acute myeloid leukemias (AMLs).
Treatment with HDACi alone results in a modest change in the pattern of gene expression within several cell types, supporting a model that additional events are required for inducing transcription. Therefore, it is expected in the case of promoters regulated by AML-1 fusion genes recruiting the HDAC complex, that HDACi will not be sucient to convert the repressor fusion gene itself to a transcriptional activator. There is signi®cant in vitro data to support the combination of RA and HDACi to synergize dierentiation induction in several AML cell lines. Signaling pathways that interact with RA mediated transcription may be modulated by HDACi to achieve dierentiation of non-APL myeloblasts. Particularly appealing in this category are cytokines such as G-CSF, interferon a or g and vitamin D3 induce or synergize RA induced myeloid dierentiation in several leukemic cell lines (Chelbi-Alix and Pelicano, 1999; Jansen et al., 1999; Makishima et al., 1999) . Novel prodrugs that release an HDACi and a speci®c dierentiation agent inside the cell are under development (Mann et al., 2001) .
The clinical application of these interesting observations are presently in progress. One patient with APL in relapse and insensitive to RA treatment responded when given RA in combination with sodium phenylbutyrate (NaPB), a putative HDACi which increased histone acetylation in peripheral mononuclear cells . Unfortunately, ®ve additional cases in this category failed to show a clinical response despite increasing histone acetylation (Novick et al., 1999) . Although both the patient who responded to this combination and several patients who failed to respond had point mutations in the PML/RARa fusion molecule, the speci®c mutations diered. A recent in vitro analysis of PML/RARa point mutations arising in patients showed signi®cant variability in the speci®c eects of each mutation on ligand binding, coregulator binding, and transcriptional activation (Cote et al., 2000) . Thus, it is possible that the precise molecular mechanism responsible for relapse may be important in determining response to therapy. Trials of combinations of dierentiation agents in non APL leukemias are also beginning. One clinical trial utilizing ATRA, sodium phenylbutyrate and GCSF in patients with AML-1 ETO relapsed AML has just been initiated . This therapy is dicult because a high concentration (mM) of sodium phenylbutyrate is required on a continuous basis for several weeks. A more eective treatment will be required for a disease known for a very rapid progression. Therefore, clinical success of this concept will depend on the development and understanding of agents that are more potent HDACi such as SAHA and depsipeptide.
Myelodysplastic syndrome (MDS) is a candidate for dierentiation therapy
MDS represents a group of disorders of multi-potent hematopoeitic progenitor cells characterized by ineective hematopoeisis, increased intramedullary apoptosis, and incomplete dierentiation which may progress to acute leukemia (Novitzky, 2000; Saba, 2001) . MDS is associated with complex karyotypic abnormalities which appear to increase with age suggesting accumulating genetic damage as its underlying pathology. Speci®c defects such as loss of chromosome 5q are associated with a relatively mild form of disease, however, candidate tumor suppressor genes have not been found. MDS is associated with aberrant methylation of certain genes (Nguyen et al., 2001 (Dobosy and Selker, 2001) . However, methylated genes can be activated by the combination of HDACi and 5 Aza-2' deoxycytidine (Cameron et al., 1999) . Genes known to be methylated in MDS and myeloid leukemia include the cell cycle inhibitor p15
INK4b , p16 and E-cadherin (Teo®li et al., 2001; Toyota et al., 2001) . Hypermethylation of p15 and other key genes may contribute to the dierentiation block seen in MDS. Thus, blockade of DNA methylation, combined with stimulation of transcription by HDACi may regulate gene-expression and stimulate hematopoeisis, decrease apoptosis and lead to clinical response in MDS.
In order to evaluate therapy in MDS, whether it be dierentiation induction or selective apoptosis, better genetic classi®cations are required to understand therapeutic outcome. Speci®c markers of dierentiation are dicult to assess and the ability to change global histone acetylation or methylation in myeloid cells following treatment may not predict or correlate with clinical outcome. To evaluate novel therapies and surrogate markers in this group of diseases, selected genes targeted for modulation of methylation should be evaluated for expression by chromatin immunoprecipitation assay and for their state of methylation.
Signaling pathways to be considered in developing dierentiation therapy
Monocytic dierentiation of leukemic cells can be induced by agents such as 12-0-tetradecanoylthorbol-13-acetate (TPA) in cell lines and primary culture of leukemic cells (Davis et al., 1997) . TPA has been administered to patients with myeloid leukemias in China (Han et al., 1998) . Clinical responses were observed in some patients, without evidence of myelosuppression and with acceptable dose dependent and reversible toxicity. However, these studies did not evaluate dierentiation. A current phase I ± II trial using TPA in patients with relapsed/refractory hematologic malignancies and other bone marrow disorder is presently in progress in the USA (Strair et al., 2001) . Treatment with TPA has resulted in signi®cant decreases in number of circulating leukemic cells and a partial response in a patient with Hodgkin's disease. The study shows that TPA stays in the circulation for several hours and treatment is associated with some induction of dierentiation in circulating leukemic cells.
cAMP-dependent signal transduction cooperates with retinoids to induce myeloid dierentiation of human leukemia cell lines (Gianni et al., 1995) . In one APL cell line resistance to RA induced dierentiation could be reversed by the addition of cAMP analogs (Ruchaud et al., 1994) . Another study reports that stimulation of TNF pathways can overcome RAresistance in several APL cell lines (Witcher and Miller, 2001) . These studies of interacting signal transduction pathways may suggest novel combination strategies. For example, recent studies have determined that treatment of APL patients with RA incorporated into liposomes resulted in higher plasma RA levels than that obtained with oral RA, and in a high percentage of remission without minimal residual disease as measured by PCR (Douer et al., 2001 ). Placing a cAMP or TNF analog with RA into liposomes for delivery for treatment of various hematologic malignancies would have the additional advantage of protecting the cAMP analog from enzymatic degradation and may enhance the eectiveness of RA.
Vitamin D3 (1,25 dihydroxycholecalciferol, calcitral) alone or in synergistic combination with HDACi induces myeloid dierentiation in several leukemic cell lines Shiohara et al., 2001) . This is associated with induction of p21 WAF1 , cell cycle arrest and, at higher concentration, with induction of apoptosis . Recent studies have demonstrated that dexamethasone potentiates the antiproliferative eect of calcitral and decreases calcitralinduced hypercalciemia. Clinical studies have demonstrated that high doses of calcitral and dexamethasone can be safely tolerated and that they enhance the eect of chemotherapeutic agents such as paclitaxel and carboplatin (Trump et al., 2001) . Follow up studies are being performed or planned for patients with a variety of hematological malignancies.
Combining old with new therapies
The main treatment used in hematologic malignancies is combination cytotoxic chemotherapy. Leukemias such as APL, AML-1/ETO, TEL/AML-1, associated with fusion leukemogenic transcription repressor proteins, respond favorably to chemotherapy. Cell lines derived from APL and HL-60 cell lines respond to anthracyclines by dierentiation and apoptotis (Schwartz et al., 1983; Chikayama et al., 1998; Fenaux et al., 2001) . More interestingly, APL in particular has a high remission induction rate following treatment with anthracyclines. This suggests that dierentiation may play a role in the elimination of residual tumor cells after cytotoxic therapy. Indeed, there is in vivo evidence that dierentiation of leukemic blasts during chemotherapy treatment, especially in leukemias with fusion genes and proteins, predicts a longer duration of remission (Raza et al., 1993) .
Combining chemotherapy with dierentiation therapy (Figure 1) is schedule dependent as shown in vitro and in vivo. In several leukemic cell lines, pretreatment with certain chemotherapeutic agents followed by dierentiation inducers such as retinoic acid, butyrates or HMBA results in enhanced dierentiation and apoptosis (Huang and Waxman, 1994; Waxman et al., 1990) . These data, in turn, suggest speci®c therapies to induce durable remissions in leukemia. However, this strategy must be carefully applied, based on research into mechanisms by which dierentiation and apoptotic pathways interact. Dierentiation of APL cells, ®rst treated with RA, blocks arsenic trioxide and anthracycline induced apoptosis, possibly due to induction of Bcl-2/A 1 (Jing et al., 2000) . Nevertheless, combination of these two agents results in greater TRAIL-mediated apoptosis (Altucci et al., 2001) . Treatment with certain chemotherapeutic agents may arrest leukemic cells in G 1 eliciting a greater response to the subsequent use of dierentiation agents. The dierentiating leukemic cells, pre-treated with chemotherapy, lose repair and anti-apoptotic programs and become more responsive to the cytotoxic induction of apoptosis (Huang et al., 1995; Scher et al., 1982a) . This synergy may be cancer cell selective in that dierentiation induction is not aberrant in normal cells and consequently the combined toxicity does not aect normal proliferating cells (Waxman et al., 1990) . Interestingly, in primary cultures of leukemic blasts obtained from patients, additions of low doses of chemotherapy with the combination of dierentiation agents has resulted in a higher dierentiation induction than the individual agents (Hassan et al., 1991) . This is consistent with the clinical observation that duration of remission in patients with APL is signi®cantly longer following RA combined with chemotherapy as compared to ATRA followed by chemotherapy. Protocols need to be developed to evaluate the clinical ecacy of combination cytotoxic dierentiation therapy in treating hematologic malignancies.
Future directions
Therapeutic targeting of protein-protein interactions that have been identi®ed as mediators of transcriptional repression that blocks hematopoeitic dierentiation should be further explored. An example is PLZF, a zinc ®nger DNA binding protein that functions as a repressor of transcription (Melnick and Licht, 1999) . PLZF was initially identi®ed as a portion of the leukemogenic fusion protein PLZF RARa in the RA resistant t(11;17) form of APL (Chen et al., 1993) (Figure 2 ). AML-1 alone or as part of AML-1 ETO or TEL AML-1 interacts with PLZF and inhibits the transcriptional repression function of PLZF (Melnick et al., 2000b, Guidez and . These protein ± protein interactions are sites for therapeutic targeting since they also involve aberrant HDAC recruitment.
Bcl-6, a protein that is rearranged and overexpressed in at least 40% of diuse large cell lymphoma (DallaFavera et al., 1996) similar to PLZF, inhibits transcription of genes that mediate dierentiation and growth arrest of lymphoid cells. PLZF and Bcl-6 both transcription repressors contain within their protein a POZ/BTB structure domain (Dhordain et al., 2000) that is required for the recruitment of N-CoR (Deltour et al., 1999) . PLZF uses the BTB domain to form homodimers, the crystal structure of which has been solved and the key sites of the BTB domain that are required for direct co-repressor binding has been identi®ed (Melnick et al., 2000a) . This site represents an attractive therapeutic target to overcome transcriptional repression in some acute leukemias and diuse large cell lymphoma.
Screening compounds utilizing combinatorial proteomic techniques will be useful in identifying speci®c inhibitors to overcome site-speci®c transcriptional repression due to fusion leukemogenic protein production or interactions. The use of anti-sense oligonucleotides to abrogate leukemogenic fusion transcription factors such as shown for PML-RARa or antiapoptotic proteins, such as Bcl-2, appears promising (Gambacorti Passerini et al., 1996) . The remarkable clinical eect of STI571 in blocking the tyrosine kinase activity of the BCR Abl gene in CML (Druker et al., 2001 ) is another example of a selective and targeted therapy. Targeted therapies such as RA in APL and STI571 in CML are eective in chemotherapy resistant patients. However they should ideally be used as part of the initial treatment since relapse from chemotherapy treatment is often associated with additional genetic lesions in the malignant cell, an outcome that may diminish the curative potential of targeted siteselective therapies.
The recent development of cyclin-speci®c inhibitors will be useful in combination with dierentiation inducers. As previously stated, agents designed to inhibit speci®c cyclin function involved in G1 progression should also enhance dierentiation by various inducers. Thus, cyclin-dependent kinase inhibitors should be explored in combination with clinically proven dierentiation inducers such as retinoids and butyrates. Blocking ubiquitination and degradation of normal proteins whose function is inhibited by oncogenic fusion proteins should also be considered as a means of shifting the balance away from the oncoprotein and overcoming the leukemogenic transcription repression. Reports that lithium or G-CSF enhance RA induced dierentiation by inhibiting degradation of RARa in WEHI leukemia cells support this approach (Finch et al., 2000) .
Eorts should be made to develop more potent chemical dierentiation inducers of hematologic malignant cells since there is clinical evidence that drugs designed as dierentiation inducer may be eective. For example, HMBA treatment resulted in measurable dierentiation and clinical responses in some patients with chemotherapy refractory acute leukemia and myelodysplastic syndrome (Rowinsky et al., 1992) . The treatment was relatively non-toxic but required high concentrations of the drug for long duration, illustrating the need to identify new agents. A variety of chemically related compounds have been synthesized and currently, members of this class have been identi®ed that have increased potency, perhaps because they can also act as HDACi (Richon et al., 2001) . In another approach, a RA dierentiation insensitive NB4 cell line ) was used to screen over 400 cytostatic compounds for their ability to enhance myeloid dierentiation. This resulted in the identi®ca-tion of a dithiophene phenol-ester (DPE) that induces dierentiation at 10 nM concentration, and overcomes transcriptional repression of PML RARa by a mechanism which does not involve histone acetylation (Waxman, 2001) . Interestingly, DPE in combination with RA induces the expression of several genes that are not observed when RA alone or in combination with butyrate is used to treat NB4 cells. A ®vefold greater concentration of this compound induces apoptosis that is not RA dependent. DPE is now being evaluated in animal tumor models.
It has been known for sometime that fetal globin, a repressed gene in adult erythroid cells can be reexpressed following treatments with hydroxyurea, cytosine arabinoside and various forms of butyrates. Combinations of hydroxyurea, cytosine arabinoside and butyrates or other dierentiation inducers show a synergistic eect in induction of dierentiation in several human leukemia cell lines suggesting alternative pathways (Niitsu et al., 1997) . Recent studies in the clinic have demonstrated that fetal globin expression is sustained even when the dierentiation inducer is used intermittently and that such treatment is clinically eective in patients with sickle cell disease (Atweh and Schechter, 2001 ). Thus, rather than continuous infusions which pose practical diculties, pulses of dierentiation inducers may also be eective in treating hematologic malignancies. This approach requires surrogate markers of dierentiation in order to establish the ecacy of a newly designed schedule.
These are but a few examples to identify more speci®c agents and therapeutic schedules for dierentiation therapy. A major breakthrough achieved with dierentiation therapy in APL underscores the validity of this approach. Given the similarity of single lesions in several other forms of leukemia resulting in transcriptional repression, often involving identical corepressors, a concerted eort should be made to develop clinical trials with presently available agents to identify the next example of a successful dierentiation therapy.
